BEOVU in the Treatment of Dystrophy-related Macular Neovascular Degeneration

Brolucizumab-dbll (BEOVU®) Intravitreal Injection in the Treatment of Dystrophy-related Macular Neovascular Degeneration

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04690062

Enrollment

Registered

2020-12-30

Start date

2020-10-25

Completion date

2022-12-30

Last updated

2020-12-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dystrophy, Retinal

Keywords

macular degeneration, BEOVU, RETINAL DYSTROPHY

Brief summary

Dystrophy-Related macular neovascularization degeneration occur is a vision threatening condition.The investigators evaluate the efficacy of BEOVU intravitreal treatment.

Detailed description

Baseline ,and postoperative 1 ,6 and 12 months full ophthalmic examination was done. Procedure included intravitreal injection of Brolucizumab (BEOVU®, Genen-tech, South Francisco, CA)

Interventions

DRUGBrolucizumab-Dbll

intravitreal injection of Brolucizumab (BEOVU)

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 50 Years

Healthy volunteers

Inclusion criteria

* Dystrophy-Related macular neovascularization degeneration

Exclusion criteria

* age related macular degeneration , other causes of macular neovascularization degeneration

Design outcomes

Primary

Measure	Time frame	Description
Best corrected visual acuity (BCVA)	12 months	Change in BCVA in LOG MARS(logarithm minimum angle of resolution)

Secondary

Measure	Time frame	Description
optical coherence tomography (OCT) foveal thickness	12 months	change in foveal thickness measured in micrometer

Countries

United Arab Emirates

Contacts

Primary ContactTarek R Elhamaky, MD

thamaky@ibnnafees.com+97126324200

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026